The Febrile Neutropenia Market Economic Outlook indicates steady growth driven by the rising number of chemotherapy patients and increasing awareness of neutropenia-related complications. The market is being shaped by innovative therapies, cost-effective biosimilars, and advanced patient care strategies. Granulocyte colony-stimulating factors (G-CSFs) remain the primary treatment, complemented...